Pivmecillinam
Brand names: Pivya · Active ingredient: Pivmecillinam Hydrochloride
In short: PIVYA is indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli (E. coli), Proteus mirabilis, and Staphylococcus saprophyticus.
What is Pivmecillinam used for?
PIVYA is indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of
Escherichia coli (E. coli),
Proteus mirabilis, and
Staphylococcus saprophyticus.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIVYA and other antibacterial drugs, PIVYA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Pivmecillinam dosage
The recommended dosage of PIVYA is one 185 mg tablet orally 3 times a day for 3 to 7 days as clinically indicated. Administer PIVYA with or without food
.
PIVYA (pivmecillinam) is a prodrug of mecillinam (the active antibacterial agent)
.
If a dose of PIVYA is missed, instruct patients to take the dose as soon as possible. Do notdouble the dose to make up for the missed dose.
How to take Pivmecillinam — instructions & advice from the label
Hypersensitivity Reactions
Advise patients that allergic reactions, including serious allergic reactions, could occur with PIVYA and that serious reactions require immediate treatment. Ask patients about previous hypersensitivity reactions to penicillins, cephalosporins, carbapenems, and other beta-lactam antibacterials. Advise the patient to call their healthcare provider immediately if they develop a new rash, urticaria, drug eruptions, swelling of the face, difficulty in breathing or other symptoms of allergic reactions
.
Severe Cutaneous Adverse Reactions
Advise patients about the signs and symptoms of severe cutaneous adverse reactions. Advise the patient to discontinue PIVYA if they develop any type of skin rash, mucosal lesions or any other sign of hypersensitivity and to seek immediate medical attention
.
Drug Interactions
Advise patients to avoid use of valproic acid, valproate or other pivalate-generating drugs due to increased risk of carnitine depletion
.
Diarrhea
Counsel patients that diarrhea is a common problem caused by antibacterial drugs, including PIVYA, and it usually ends when the drug is discontinued. …
Warnings & precautions
Do not take this medicine if: PIVYA is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to PIVYA or other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins) .
PIVYA is contraindicated in patients with primary or secondary carnitine deficiency resulting from inherited disorders of mitochondrial fatty acid oxidation and carnitine metabolism, and other inborn errors of metabolism (e.g., methylmalonic aciduria, or propionic acidemia) .
PIVYA is contraindicated in patients suffering from porphyria as pivmecillinam has been associated with acute attacks of porphyria
.
Serious hypersensitivity reactions (anaphylaxis) have been reported in patients treated with PIVYA
. These reactions are more likely to occur in individuals with a history of penicillin, cephalosporin, or carbapenem hypersensitivity or a history of sensitivity to multiple allergens. Before initiating therapy with PIVYA, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, carbapenems, and other beta-lactams because cross-hypersensitivity has been reported. PIVYA is contraindicated in patients who have experienced a serious hypersensitivity reaction
. If an allergic reaction occurs, discontinue PIVYA and institute appropriate therapy.
Severe Cutaneous Adverse Reactions (SCAR) including Acute Generalized Exanthematous Pustulosis (AGEP), Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported with PIVYA
.
Monitor patients closely and discontinue PIVYA at the first signs or symptoms of SCAR or other signs of hypersensitivity.
Clinical manifestations of carnitine depletion may occur with pivalate-containing compounds, including PIVYA. …
Pivmecillinam side effects
The following clinically significant adverse reactions are described in greater detail in the Warnings and Precautions section of labeling:
Hypersensitivity Reactions
Severe Cutaneous Adverse Reactions
Carnitine Depletion
Acute Porphyria
Clostridioides difficile-Associated Diarrhea
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of PIVYA was evaluated in 579 adult female patients with uUTI who received PIVYA at a dose of 185 mg three times daily, or at higher daily doses (not approved for PIVYA) for 3 to 10 days in a placebo controlled trial (Trial 1, N=282), an active controlled trial (Trial 2, N=213) and an open label trial (Trial 3, N=84). The majority of patients were White women between 18 and 91 years of age.
No serious adverse reactions were reported in patients treated with PIVYA in the trials.
In Trial 1, the most common adverse reactions observed in ≥2% of the patients receiving PIVYA included nausea (4.3%) and diarrhea (2.1%).
In Trial 2 and Trial 3, the most common adverse reaction occurring in ≥1% of patients receiving PIVYA was nausea with an incidence of 1.4% in Trial 2 and 3.6% in Trial 3.
Table 1 lists the most frequently reported adverse reactions occurring in ≥1% of patients receiving PIVYA in Trial 1. …
Drug interactions
Avoid concurrent treatment with valproic acid, valproate, or other pivalate-generating drugs. If concomitant use with PIVYA is necessary, counsel patients to monitor adverse reactions associated with carnitine depletion (e.g., hypoglycemia, muscle aches, fatigue, and confusion)
.
Pivmecillinam is a pivalate-generating prodrug
. Pivalate can be activated to a coenzyme-A thioester in cells which is further converted to pivaloylcarnitine and excreted in urine. Pivalate elimination associated with concomitant use of pivmecillinam with other pivalate-generating drugs decreases carnitine concentrations in plasma which may increase the risk of carnitine depletion-associated adverse reactions
.
Clearance of methotrexate from the body can be reduced by concurrent use of drugs in the penicillin class, including PIVYA. Where possible, consider alternative therapy.
Treatment of a pregnant individual with PIVYA prior to delivery may cause a false positive test for isovaleric acidemia in the newborn as part of newborn screening. Prompt follow-up of a positive newborn screening result for isovaleric acidemia is recommended.
About this medicine
PIVYA tablets contain pivmecillinam (as pivmecillinam hydrochloride), a penicillin class antibacterial for oral administration. The chemical name of pivmecillinam hydrochloride is methylene 2,2-dimethylpropanoate (2S,5R,6R)-6-[[(hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate hydrochloride. The molecular formula for pivmecillinam hydrochloride is C21H33N3O5S·HCl. The molecular weight of pivmecillinam hydrochloride is 476.0 g/mol.
Figure 1: Chemical Structure of Pivmecillinam Hydrochloride
Each film-coated PIVYA tablet for oral administration contains 185 mg pivmecillinam (equivalent to 200 mg pivmecillinam hydrochloride), and the following inactive ingredients: cellulose microcrystalline, hydroxypropyl cellulose, hypromellose, magnesium stearate, paraffin, and simethicone.
How it works: PIVYA is an antibacterial drug . …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 440a5f17-ab11-0fc8-e063-6394a90a58e9. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin